GALAHAD Phase 2 trial

October 9, 2019

Zejula Granted FDA’s Breakthrough Therapy Status for Treating Metastatic Castration-resistant Prostate Cancer

News

The oral ovarian cancer treatment Zejula (niraparib) has been given Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate ... Read more

March 11, 2019

Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients

News

Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), ... Read more